Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta
The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI. 3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrieved.
Currently, follitropin delta is approved for use via a dosing algorithm based on serum anti-Müllerian Hormone (AMH) and bodyweight individualised for each patient, and aims to obtain an ovarian response which is associated with a favourable safety/efficacy profile. The clinical value of this approach has been well established 4,5,6,7,8, particularly in treatment-naïve patients where the algorithm aims to achieve 8–14 retrieved oocytes while minimising the risk of ovarian hyperstimulation syndrome (OHSS) to optimise the live birth rate in a fresh and frozen transfer cycle. 4,5,6,7,8
Key Findings:
Ovarian Response: Both treatment groups achieved a mean of 9.9 oocytes retrieved, indicating similar efficacy
Clinical Pregnancy Rates: Clinical pregnancy rates were similar for follitropin delta 31.6% versus 31.0% for follitropin alfa
Drug Product Usage: After measurement unit conversion, the mean total dose patients were exposed to was numerically lower for follitropin delta (143.7±33.6 µg) than follitropin alfa (154.3±23.1 µg or 2,105±315 IU)
OHSS Rates: Early OHSS rates were low (2.5% for follitropin delta and 3.0% for follitropin alfa), with no cycle cancellations due to excessive ovarian response on either arm of the study.
Dr Andrea Bernabeu, Medical Director at Instituto Bernabeu and principal investigator of the ADAPT-1 trial, said: "No patients we see as fertility doctors are the same and the ability to optimise therapy based on patients age, treatment goal and whether they have a high or low response to follicular stimulation are all relevant. These data provide confidence and expand our understanding for dosing in follitropin delta."
Pierre-Yves Berclaz, Chief Science and Medical Officer at Ferring Pharmaceuticals, stated: "The ADAPT-1 trial results confirm the efficacy and safety of follitropin delta across the full range of dosing strategies, making it the only recombinant FSH with robust clinical evidence supporting multiple dosing strategies. Ferring will take forward the implications of this study in future dialogue with regulatory authorities."
About GnRH protocols
Gonadotrophin-releasing hormone (GnRH) agonists and antagonists are used as concomitant treatment during ovarian stimulation to prevent premature luteinisation and ovulation for IVF/ICSI. 7,8
About Follitropin Delta (Rekovelle ®)
Follitropin delta is a human cell line-derived rFSH with an approved dosing algorithm designed for a predictable ovarian response. 3 It is the first rFSH derived from a human cell line (PER.C6 ® cell line). Follitropin delta is structurally and biochemically distinct from other existing rFSH gonadotrophins. 3,4 Follitropin delta is approved in certain markets for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as IVF or ICSI cycle. The individualised dosing of follitropin delta is determined using an approved algorithm, based on a woman's AMH level and body weight. 3,5 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. 5,6 The follitropin delta dose should be based on AMH level, measured using the ELECSYS AMH Plus immunoassay from Roche, the ACCESS AMH Advanced from Beckman Coulter, or LUMIPULSE G AMH from Fujirebio. 3
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine with a strong heritage in areas of gastroenterology and urology, and are at the forefront of innovation in uro-oncology gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which market its medicines in over 100 countries.
Learn more at www.ferring.com, or connect with us on LinkedIn, Instagram, YouTube, Facebook and X.
REFERENCES
1 – Arce JC, Larsson P, Garcia-Velasco JA; Establishing the follitropin delta dose that provides a comparable ovarian response to 150 IU/day follitropin alfa; RBMO; 2020
2 – Yang R, Zhang Y, Liang X et al; Comparative clinical outcome following individualized follitropin delta dosing in Chinese women undergoing ovarian stimulation for in vitro fertilization / intracytoplasmic sperm injection; Reproductive Biology and Endocrinology; 2022
3 – Clinical Trials.gov page: https://clinicaltrials.gov/study/NCT05263388 (Accessed June 2025)
4 – Andersen, A. N., Nelson, S. M., Fauser, B. et al. (2017). Individualized versus conventional ovarian stimulation for in vitro fertilization: A multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertility and Sterility, 107(2), 387-396.
5 – Bosch E, Havelock J, Martin FS, Rasmussen BB, Klein BM, Mannaerts B, Arce JC; ESTHER-2 Study Group. Follitropin delta in repeated ovarian stimulation for IVF: a controlled, assessor-blind Phase 3 safety trial. Reprod Biomed Online. 2019 Feb;38(2):195-205. PMID: 30594482.
6 – Ishihara O, Arce JC, Japanese Follitropin Delta Phase 3 Trial G. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. Reprod Biomed Online. 2021 May;42(5):909-18. PubMed PMID: 33722477. Epub 2021/03/17.
7 – Qiao J, Zhang Y, Liang X, et al. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Hum Reprod. 2021 Jun 28;36(9):2452-62. PubMed PMID: 34179971. Epub 2021/06/29.
8 – Blockeel C, Griesinger G, Rago R, et al. Prospective multicenter non-interventional real-world study to assess the patterns of use, effectiveness and safety of follitropin delta in routine clinical practice (the PROFILE study). Frontiers in Endocrinology. 2022 Dec 22;13:992677. PMID: 36619578.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
Hassett on healthcare coverage cuts: ‘Best way to get insurance is to get a job'
National Economic Council Director Kevin Hassett said the best way for people to get health insurance is to get a job while discussing the massive tax cut legislation, which dramatically upends health care, signed into law by President Trump. During an appearance on CBS News's 'Face The Nation,' Hasset was asked about Americans' concerns that about 12 million Americans could lose Medicaid coverage, according to a report by the Congressional Budget Office (CBO). However, Hasset said that the CBO made a similar claim when the Trump administration aimed to add work requirement waivers to Obamacare in 2017, stating that the number of insured people increased instead. 'The bottom line is, the best way to get insurance is to get a job,' he said. 'And we've got a 'big, beautiful bill' that's going to create a lot of job creation and a lot of insurance, and the CBO is just not accounting for that.' The bill enacts the country's first-ever requirement for adults under the age of 65 — including low-income parents of children older than 14 — to prove they work, volunteer or attend school at least 80 hours per month. 'The idea that that's going to cause a massive hemorrhaging in availability of insurance doesn't make a lot of sense to us,' he said. Hassett also claimed that 5 million of those who are losing insurance have other insurance, which he says the CBO did not take into account 'They're people who have two types of insurance,' he added. 'And so therefore, if they lose one, they're still insured.' Hassett insisted that no one will lose their insurance. 'It's sound budgetary politics. And I think that nobody's going to lose their insurance,' he said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Health Line
6 hours ago
- Health Line
Medication for Migraine Headaches
Key Takeaways Medications for migraine either prevent episodes or relieve symptoms, with options like pills, injections, and nasal sprays available. Acute medications provide relief during a migraine, while preventive medications reduce the frequency and severity of episodes. Some people may need both. Various acute and preventive medications exist, including pain relievers, ergotamines, triptans, CGRP antagonists, anti-nausea drugs, and others like beta-blockers and antidepressants. Migraine is a condition in which you experience severe, debilitating headaches, involving intense throbbing or pulsing in one area of your head. The headaches are often accompanied by nausea, vomiting, and sensitivity to light and sound. There's no cure for migraine, but some medications can provide pain relief and improve your quality of life. There are two categories of medications used to help treat migraine: Acute medications: These help provide relief from pain and other symptoms during a migraine attack. Preventive medications: These aim to reduce the frequency and severity of chronic migraine attacks. Some people may need medications for acute treatment only, while others may need a combination of the two types of medication. The best treatment plan will depend on the type, severity, and frequency of your migraine attacks. Keep reading to learn more about the different types of medications to help treat migraine. Drugs for acute treatment These medications should be taken at the onset of migraine symptoms to relieve a headache, reduce its severity, or prevent it from progressing. Taking any of these drugs too often may lead to a medication overuse (rebound) headache. This type of headache may arise from overusing medication and adapting to its effects. If you need to use acute migraine drugs more than 10 days per month, speak with a healthcare professional. They may suggest other treatments, such as preventive medications. Here are the different types of acute medications for migraine: Pain relievers Some over-the-counter (OTC) pain relievers may help treat migraine. These include: Some OTC drugs marketed specifically for migraine combine one or more of the drugs above with a small amount of caffeine. This can make them work more quickly and effectively, especially for mild migraine. If OTC pain relievers don't help treat migraine symptoms, a doctor may prescribe stronger doses. But it's important to be aware of the possible side effects of long-term NSAID use. These include: Learn more about OTC medications for migraine. Ergotamines Ergotamines were the first class of drugs used specifically for migraine. They help treat vascular headaches by targeting 5HT-1B and 5HT-1D receptors, which contract the blood vessels around your brain. They're not commonly prescribed anymore since more effective medications are now available. They also have potentially dangerous side effects that could affect your brain, heart, and cardiovascular system. But if your migraine attacks are frequent or last longer than 48 hours, a doctor may still recommend some ergotamines, such as: dihydroergotamine (DHE-45, Migranal) ergotamine (Ergomar) ergotamine and caffeine (Cafatine, Cafergot, Cafetrate, Ercaf, Migergot, Wigraine) Talk with a healthcare professional before taking ergotamines, especially if you: are pregnant have heart disease are taking other medications, such as antifungals or antibiotics Triptans Triptans increase serotonin levels in your brain, reducing inflammation and constricting blood vessels to effectively end a migraine attack. Triptans are available in the form of pills, nasal sprays, injections, and tablets that dissolve under your tongue, and they work quickly to stop a migraine attack. Triptans available to help treat migraine include: almotriptan (Axert) eletriptan (Relpax) frovatriptan (Frova) naratriptan (Amerge) rizatriptan (Maxalt, Maxalt-MLT) sumatriptan (Imitrex) zolmitriptan (Zomig) You should not take triptans more than 10 times per month. Additionally, you should not take triptans if you: have had a stroke have heart disease have hypertension (high blood pressure) have angina are pregnant have hemiplegia have basilar migraine Possible side effects of triptans include: drowsiness hot or cold flashes dizziness nausea tingling or numbness in your toes tightness or discomfort in your chest or throat Triptans may also cause serotonin syndrome if taken with other drugs that increase serotonin, such as antidepressants. This may be life threatening. Learn more about triptans for migraine. Calcitonin gene-related peptide (CGRP) antagonists CGRP antagonists, also known as gepants, are the newest group of medications approved for treating and preventing migraine. They work on calcitonin gene-related peptide (CGRP), a protein found around your brain that is involved in the pain associated with migraine. Current CGRP antagonists approved to treat acute migraine include: rimegepant (Nurtec) ubrogepant (Ubrelvy) zavegepant (Zavzpret) Learn more about CGRP antagonists for migraine. Anti-nausea drugs These drugs may help reduce nausea and vomiting that can occur during a severe migraine episode. They're usually taken along with a pain reliever since they don't reduce pain. Anti-nausea medications include: dimenhydrinate (Gravol) metoclopramide (Reglan) prochlorperazine (Compazine) promethazine (Phenergan) trimethobenzamide (Tigan) These drugs may make you drowsy, less alert, or dizzy, and they have other possible side effects. Learn more about anti-nausea medications. Opioids If migraine pain doesn't respond to other pain relievers and you can't take ergotamines or triptans, you may receive opioids during hospitalization for migraine. However, some research suggests that opioid use may increase the risk of effects such as: worse headaches opioid dependence reduced quality of life For this reason, it's important to discuss other treatment options with a healthcare professional. Drugs for preventive treatment If you're living with chronic migraine, a healthcare professional may prescribe a medication to help: prevent migraine episodes reduce symptom intensity, duration, and severity improve your quality of life Possible preventive medications for migraine include: CGRP monoclonal antibodies, such as erenumab (Aimovig), fremanezumab (Ajovy), eptinezumab (Vyepti), and galcanezumab (Emgality) CGRP receptor antagonists, such as atogepant (Qulipta) and rimegepant (Nurtec) beta-blockers, such as metoprolol (Toprol XL) and propranolol (Inderal) calcium channel blockers, such as diltiazem (Cardizem, Cartia XT, Dilacor, Tiazac) and verapamil (Calan, Covera, Isoptin, Verelan) antidepressants, such as amitriptyline (Elavil, Endep) and fluoxetine (Prozac, Sarafem) anticonvulsants, such as topiramate (Topamax) and valproate (Depakene) These drugs are taken on a regular basis, usually daily, and may be prescribed alone or in combination with other drugs. It may take several weeks or months for them to become effective. The Food and Drug Administration (FDA) has also approved Botox (Botulinum toxin type A) injections for the treatment of chronic migraine. Generally, injections are repeated every 3 months and can be costly. Speak with a healthcare professional about the potential side effects of each medication. Frequently asked questions What is the best medication for migraine? The best medication will depend on the frequency, severity, and intensity of your migraine. If you sometimes experience migraine, then OTC or prescription pain relievers may be enough. However, if you experience migraine attacks more than 10 days per month, you may need preventive medications. What is the drug of choice for migraine attacks? Many drugs are effective and recommended for migraine treatment. The best medication will depend on several factors, such as the type and severity of your migraine attacks and any underlying health conditions you have. What is the first-line choice for migraine prevention? First-line medications for migraine episode prevention include divalproex, timolol, frovatriptan, metoprolol, topiramate, and propranolol.
The Hill
a day ago
- The Hill
Beshear on potential White House bid: ‘I'll think about it after next year'
Gov. Andy Beshear (D-Ky.) said he'll consider a 2028 White House bid in an article published Friday while seething over the 'big, beautiful bill' backed by Republicans in Congress. 'Two years ago, I wouldn't have considered [running for president]. But if I'm somebody who could maybe heal and bring the country back together, I'll think about it after next year,' Beshear told Vanity Fair. The Kentucky governor's term ends in 2027 and he's pledged to complete his tenure in office before launching another political bid for a higher office. Fellow party members Gov. Gavin Newsom (D-Calif.), Rep. Alexandria Ocasio-Cortez (D-N.Y.) and Gov. Josh Shapiro (D-Pa.) have also been listed as potential contenders for the presidency as Democrats look to claw back the executive branch after their November loss. Political pundits have suggested the GOP-authored spending package will have a significant impact on midterm elections and cycles that follow as Americans grapple with the possibility of losing their healthcare coverage, a top issue for Beshear. 'What the Republican majority is getting wrong is that the American people don't view health care in a partisan way. They want to be able to see their doctor when they need to, and they want their neighbor to be able to see their doctor,' Beshear, Kentucky's former attorney general, said in the interview. 'No state will be able to compensate for the level of devastation that this bill would cause. What they're doing is immoral, and it's certainly not Christian,' he added. The legislation is set to remove millions from Medicaid and introduce stricter work requirements for food stamp benefits and other social services. However, Beshear said in order to break through on the cuts, Democrats will need to help voters conceptualize the ongoing impact of the bill. 'If Democrats say this bill is going to increase food insecurity, their point's not going to get through. If they say people are going to go hungry, it will,' he said. 'And we have to explain not just what we disagree with in this bill, but why. And my why is my faith. The parable of the fishes and the loaves is in every book of the gospel. My faith teaches me that in a country that grows enough food for everyone that no one should starve.'
